MedPath

Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

Not Applicable
Completed
Conditions
Vaccine Refusal
Covid19
Registration Number
NCT04871776
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3671
Inclusion Criteria
  • Patients in the Mass General Brigham system
  • Aged 18 and older
  • Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit
Exclusion Criteria
  • Documented allergy to a COVID vaccine or its components
  • Home address outside of Massachusetts
  • Did not receive full set of primary COVID-19 vaccination series

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Received a Booster Vaccination Through the Targeted Visit2-5 days

Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.

Secondary Outcome Measures
NameTimeMethod
Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit6 weeks after the target visit

Number of participants who received one dose of a COVID booster vaccine between randomization through 6 weeks after the targeted visit, determined through electronic health records.

Trial Locations

Locations (1)

Mass General Brigham

🇺🇸

Boston, Massachusetts, United States

Mass General Brigham
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.